Institutional shares held 62.2 Million
355K calls
96.5K puts
Total value of holdings $3.94B
$22.5M calls
$6.1M puts
Market Cap $2.9B
45,878,200 Shares Out.
Institutional ownership 135.67%
# of Institutions 194


Latest Institutional Activity in MRUS

Top Purchases

Q2 2025
Health Invest Partners Ab Shares Held: 59.9K ($3.79M)
Q2 2025
Nelson, Van Denburg & Campbell Wealth Management Group, LLC Shares Held: 6.91K ($437K)
Q2 2025
Harbour Capital Advisors, LLC Shares Held: 14.1K ($894K)
Q2 2025
Nbc Securities, Inc. Shares Held: 1.02K ($64.3K)
Q2 2025
Klp Kapitalforvaltning As Shares Held: 10K ($633K)

Top Sells

Q2 2025
Platinum Investment Management LTD Shares Held: 44.9K ($2.84M)
Q2 2025
Harbor Capital Advisors, Inc. Shares Held: 56.4K ($3.57M)
Q2 2025
Knights Of Columbus Asset Advisors LLC Shares Held: 13.2K ($833K)
Q2 2025
Signaturefd, LLC Shares Held: 1.07K ($67.9K)
Q1 2025
Octagon Capital Advisors LP Shares Held: 308K ($19.5M)

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.


Insider Transactions at MRUS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
183K Shares
From 4 Insiders
Bona fide gift 40.6K shares
Exercise of conversion of derivative security 142K shares
Sell / Disposition
132K Shares
From 3 Insiders
Bona fide gift 40.6K shares
Open market or private sale 91.5K shares

Track Institutional and Insider Activities on MRUS

Follow Merus N.V. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRUS shares.

Notify only if

Insider Trading

Get notified when an Merus N.V. insider buys or sells MRUS shares.

Notify only if

News

Receive news related to Merus N.V.

Track Activities on MRUS